NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Baseimmune

Baseimmune

Private
LondonHealthcare & Life Scienceshttps://baseimmune.co.uk/

Last Round

Series A

Feb 26, 2024

Total Funding Raised

$17.15M

Company Overview

Baseimmune is a biotechnology company that utilizes a proprietary deep learning AI platform to predict future pathogen mutations for the development of novel vaccines and immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

vaccine designAI drug discoverycomputational biologysynthetic antigensin silico vaccine designpathogen evolutionbiotech AIvaccine R&Ddrug discovery platformantigen discoveryfuture-proof vaccinesbiotech partnershippharma R&DAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Baseimmune Comps

Public and private peers based on sector, stage, and business model.

Baseimmune comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Baseimmune Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 26, 2024
SeedNov 2, 2021
Pre SeedApr 1, 2021

Key People

Founding team and executive leadership

Ariane C. Gomes

Co-Founder And Chief Scientific Officer

Founding Team

Kevin Walton

Chief Executive Officer Board Director

Executive Team

Baseimmune Investors

Notable investors and investment history

Baseimmune investors
InvestorRounds
Merck Global Health Innovation FundSeries A
Hoxton VenturesSeries A, Seed
IQ CapitalSeries A
Rockmount Seed InvestmentsSeed, Pre Seed
Beast VenturesSeed, Series A
MakiSeed, Pre Seed, Series A
The Creator FundSeed, Series A, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 12, 2026

    Unveiled a multi-pathway immunotherapy strategy for fibrosis.

Baseimmune Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Baseimmune Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Baseimmune's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range29
Year Founded2019
Last FundingFeb 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.